Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Establishing Analytical and Clinical Similarity Between HD201 and Trastuzumab

2020 Year in Review - Biosimilars - Biosimilars

The totality of evidence generated from comparative systematic stepwise assessment of HD201 and trastuzumab reference in terms of analytical, pharmacodynamic, pharmacokinetic, and clinical similarity demonstrated the equivalence of HD201 to trastuzumab.

HD201 is a biosimilar candidate to trastuzumab indicated for the treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast and gastric cancers. At the 2020 American Society of Clinical Oncology Annual Meeting, an overview of the comparative systematic stepwise assessment of HD201 and trastuzumab reference in terms of analytical, pharmacodynamic, pharmacokinetic (PK), and clinical similarity was presented.

Bioanalytic similarity was demonstrated between HD201 and trastuzumab based on physiochemical and functional assessments. Physiochemical assessments consisted of evaluations of several quality attributes, including primary structure, higher-order structures, glycosylation, and purity/impurity by size, as well as charge variants; biological assays included those relating to mechanism of action. Analytical biosimilarity between the 2 products was demonstrated, with some minor changes in quality attributes that were not clinically meaningful. 

The program to demonstrate clinical similarity of HD201 to trastuzumab included 2 clinical studies. The first was the double-blind, randomized, parallel-group TROIKA-I study, which compared the PK and safety of HD201, EU-licensed trastuzumab, and US-approved trastuzumab in 101 healthy human subjects. The TROIKA-I study demonstrated the PK equivalence among the 3 cohorts, and that HD201 was safe and well-tolerated.

The second study (TROIKA) was a randomized, double-blind, parallel-group phase 3 trial that compared the efficacy of HD201 with EU-trastuzumab in 251 patients with HER2-positive early breast cancer. Eligible patients received HD201 or EU-trastuzumab in combination with chemotherapy as neoadjuvant therapy followed by HD201 or EU-trastuzumab alone in the adjuvant phase. The primary end point was total pathologic complete response (tpCR). In the neoadjuvant phase, patients in the HD201 group achieved a tpCR of 46.6%, whereas those in the trastuzumab group achieved a tpCR of 46.2%, with the 95% confidence interval being within the prespecified equivalence margins (–15%-15%), establishing equivalence between the 2 groups. Safety and PK profiles were comparable between the 2 groups.

The totality of evidence generated from the comparative exercise among HD201, EU-licensed trastuzumab, and US-approved trastuzumab demonstrated the equivalence of HD201 to trastuzumab.

Reference
Hii J, et al. ASCO 2020. Abstract 579.

Related Items
Rapid Biosimilar Adoption Possible in Community Oncology Practice
Charlie Dawson
TON - October 2021 Vol 14, No 5 published on October 14, 2021 in Biosimilars
Biosimilars Year in Review Introduction
2020 Year in Review - Biosimilars published on January 24, 2021 in Biosimilars
Population-Based, Real-World Data of Neoadjuvant Chemotherapy + Pertuzumab + SB3 in HER2-Positive, Early Breast Cancer
2020 Year in Review - Biosimilars published on January 24, 2021 in Biosimilars
Cost-Savings from Conversion from Reference Pegfilgrastim with On-Body Injector Device to Biosimilar Pegfilgrastim-jmdb in DLBCL
2020 Year in Review - Biosimilars published on January 11, 2021 in Biosimilars
Pharmacokinetic and Safety Equivalence Demonstrated Between HD204, a Biosimilar of Bevacizumab, in Healthy Male Subjects
2020 Year in Review - Biosimilars published on January 11, 2021 in Biosimilars
Utilization and Adherence Among Infliximab Biosimilar Initiators in a US National Commercial Insurance Database
2020 Year in Review - Biosimilars published on January 11, 2021 in Biosimilars
US Oncologists’ Perception of the Efficacy, Safety, and Willingness to Prescribe Biosimilar Cancer Therapies
2020 Year in Review - Biosimilars published on January 11, 2021 in Biosimilars
Adherence Patterns Among Patients Using Infliximab Originator and Its Biosimilars
2020 Year in Review - Biosimilars published on January 11, 2021 in Biosimilars
Outcomes in Patients with IBS Who Initiate or Switch to the Infliximab Biosimilar Infliximab-dyyb (ONWARD Study)
2020 Year in Review - Biosimilars published on January 11, 2021 in Biosimilars
Real-World Comparison of Reference Infliximab versus the Biosimilar Infliximab-abda in Inflammatory Bowel Disease
2020 Year in Review - Biosimilars published on January 11, 2021 in Biosimilars
Last modified: July 22, 2021